Skip to main content

Table 1 (abstract P03). Baseline characteristics and interim analysis data of patients with TRAPS

From: Abstracts from the ISSAID 2021 Periodic Congress

  Baseline 6 months 12 months 18 months
Number of patients, N 16 13 10 6
Females (%) 11 (69) 9 (69) 7 (70) 3 (50)
Median duration of prior CAN therapy at baseline, years (min; max) 1.0 (0; 4) 1.0 (0; 4) 1.0 (0; 4) 1.5 (0; 2)
Number (%*) of patients in disease remission (physician assessment) 9 (60.0) 9 (81.8) 7 (77.8) 4 (80.0)
Physician Global Assessment, percentage of absent/mild-moderate/severe rating 40 / 53 / 0 82 / 9 / 0 44 / 44 / 11 80 / 20 / 0
Patient assessment of current disease activity; 0–10, median (min; max) 1.5 (0; 5) 1.0 (0; 4) 1.0 (0; 6) 0.0 (0; 3)
Patient assessment of current fatigue; 0–10, median (min; max) 2.0 (0; 8) 1.0 (0; 7) 2,5 (0; 8) 4.0 (0; 7)
Number (%*) of patients without impairment of social life by the disease 4 (50) 5 (63) 2 (33) 3 (60)
CRP, SAA median (mg/dl) 0.1/0.5 0.1/0.4 0.1/0.4) 0.0/0.3
  1. *not reported for all patients
  2. CRP, c-reactive protein; SAA, serum amyloid A